Select Page
Advanced NSCLC: EC Approval of Lumykras Treatment

Advanced NSCLC: EC Approval of Lumykras Treatment

The European Commission (EC) has granted a conditional marketing authorization for Amgen’s LUMYKRAS (sotorasib) to treat advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation in adults. NSCLC is the leading lung cancer diagnosis globally and includes...
FDA Tentative Approval: Vasopressin Injectable Therapy

FDA Tentative Approval: Vasopressin Injectable Therapy

The U.S. Food and Drug Administration (FDA) has granted a tentative approval for Amphastar’s Abbreviated New Drug Application (ANDA) for an injectable vasopressin therapy to increase blood pressure in adults with vasodilatory shock. As part of the clinical syndrome of...